Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs.
J Eur Acad Dermatol Venereol
; 36(4): e266-e268, 2022 Apr.
Article
in En
| MEDLINE
| ID: mdl-34897821
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Biological Products
/
COVID-19
Limits:
Humans
Language:
En
Journal:
J Eur Acad Dermatol Venereol
Journal subject:
DERMATOLOGIA
/
DOENCAS SEXUALMENTE TRANSMISSIVEIS
Year:
2022
Document type:
Article
Affiliation country:
Italia